Earlier this week, the EMA published its Reflection paper on the use of AI in the medicinal product life cycle. As set out in our previous blog post, the EMA’s draft reflection paper was published for consultation in July 2023, and following many months of review of the feedback collected from the relevant stakeholders, the Paper has now been published. The Paper reflects the views of the EMA on the use of AI from drug discovery and non-clinical development, to clinical trials, manufacturing and post-authorisation. The Paper recognises the utility of AI in digital transformation and notes new risks that need to be mitigated to ensure patient safety and data integrity.
Continue Reading EMA adopts reflection paper on the use of Artificial Intelligence (AI)A New 2024 Code for the British Pharmaceutical Industry – “The Future is Orange”
On 23 September 2024, the Association of the British Pharmaceutical Industry (ABPI) and the Prescription Medicines Code of Practice Authority (PMCPA) published an updated Code of Practice for the pharmaceutical industry. Following an extensive consultation with over 3,000 comments, ABPI has announced that the new “orange” 2024 Code amends the previous 2021 Code in three key areas: the PMCPA constitution and procedure; the provision of prescribing information; and certain elements of the Code moving from guidance to mandatory requirements. However, there are also interesting amendments to the requirement to maintain high standards and obligation to seek a lawful basis for disclosure of transfers of value to an individual.
ABPI has said that the new Code seeks to “raise the high standards expected of pharmaceutical companies even further while also ensuring that complaints can be resolved quicker”.
Continue Reading A New 2024 Code for the British Pharmaceutical Industry – “The Future is Orange”Virtual and Digital Health Digest – September 2024
This digest covers key virtual and digital health regulatory and public policy developments during August and early September 2024 from United Kingdom, and European Union.
There have been some important reimbursement updates this month. In France, the French health regulator has issued a negative opinion on the first digital therapeutic that sought reimbursement through the PECAN pathway. This opinion suggests that while PECAN provides a more streamlined process by not requiring formal clinical trials, the regulator still expects robust data to show that the digital therapeutic is worthy of reimbursement. In the UK, the National Institute for Health and Care Excellence has published a position paper that highlights the risks of using AI for generating and reporting evidence for health technology assessments. It sets out that the use of AI in this context should be limited to situations where the value of doing so can be clearly demonstrated, and sets out guidance for companies on how to present such data and to justify the use of AI. Health technology assessment seems to be an area where AI has more readily been accepted, and industry will welcome guidance on the parameters around such use.
Continue Reading Virtual and Digital Health Digest – September 2024AI: EMA publishes guiding principles on the use of large language models (LLMs)
On 5 September 2024, the European Medicines Agency (EMA) and the Heads of Medicine Agencies (HMA) published a guidance document (the Guidance) with general principles and recommendations on the use of large language models (LLMs) in regulatory science and the regulation of medicinal products. The guiding principles for users are also summarised in a one-page factsheet.
While the Guidance is aimed at the European Union (EU) regulatory authorities, it is instructive for companies active in the Life Sciences sector. It provides useful insight into how regulators will approach the use of LLMs in their regulatory activities, the risks they have identified and how these risks can be mitigated.
The development of the guiding principles set out in the Guidance are part of the EMA’s and HMA’s multiannual AI workplan to 2028 and, according to EMA, will be subject to regular future updates.
Continue Reading AI: EMA publishes guiding principles on the use of large language models (LLMs)The European AI office and other resources relevant to high risk AI systems
In our recent blog post, we reviewed the overall impact of the new EU AI Act on the life sciences industry. The AI Act (Regulation (EU) 2024/1689), which entered into force on 1 August 2024, is the world’s first comprehensive law regulating artificial intelligence (AI). While some provisions are already applicable, the provisions relating to high risk AI systems, which are those most likely to impact the life sciences industry, will apply from 2 August 2027.
Continue Reading The European AI office and other resources relevant to high risk AI systemsVirtual and Digital Health Digest – August 2024
This digest covers key virtual and digital health regulatory and public policy developments during July and early August 2024 from United Kingdom, and European Union.
Following the UK national elections on July 4, 2024, which brought in a new government, the King delivered a speech to Parliament setting out the government’s key legislative and policy agenda. Of particular importance to the life sciences sector are the Product Safety and Metrology Bill and the Digital Information and Smart Data Bill. Although the scope and content of each bill is currently unknown, they could impact medical devices and innovative scientific research. Further, there was no artificial intelligence bill in the agenda, although the government will “seek to establish the appropriate legislation” in the future.
Continue Reading Virtual and Digital Health Digest – August 2024The EU AI Act: Impact on the Life Sciences Industry
Much has been written about the EU AI Act, which has now been published in the Official Journal as Regulation (EU) 2024/1689 and entered into force on 1 August 2024.
The AI Act is so-called “horizontal legislation”, meaning it applies across industries, and its impact will be felt from agriculture to aerospace and beyond. We are pleased to contribute an expert chapter in The International Comparative Legal Guide on the application of the AI Act to the life sciences industries, with a particular focus on the regulatory framework for so-called “High Risk AI Systems”, given the significant impact this will have on AI medical devices.
We discuss what is an AI system, when the AI Act will apply, and focus on when medical devices will be regulated as High Risk AI Systems and the associated obligations on the “provider” who is placing the AI system on the market, as well as “deployers” who use AI systems in a professional capacity. There are also some interesting questions on when pre-marketing testing can be conducted, and of course the overlap between the medical devices and new AI regimes. Finally, we set out some points that life sciences companies should consider as they prepare for the implementation of the AI Act. Do let us know if you would like to discuss further!
Virtual and Digital Health Digest – July 2024
This digest covers key virtual and digital health regulatory and public policy developments during June 2024 from United Kingdom, and European Union.
While it has been a relatively quiet month in the EU given elections in the European Parliament and in the UK (as well as other countries across the EU), agencies across the globe have published important guidance on machine-learning enabled medical devices. This includes the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) guiding principles on transparency, published together with the U.S. Food and Drug Administration (FDA) and Health Canada, and the International Medical Device Regulators Forum (IMDRF) consultation on its guiding principles on good machine learning practice (which itself follows similar guidance from MHRA, FDA, and Health Canada in 2021). This demonstrates the increased importance of international standards in this area and the need for coordination between regulatory authorities to standardize guidance for these products.
Continue Reading Virtual and Digital Health Digest – July 2024The King’s Speech: Product Safety and Metrology Bill
Following the outcome of the national election on 4 July 2024, on 17 July 2024, King Charles III gave a speech to the UK Parliament in which, as directed by the new Government, he outlined the key points of its legislative and policy agenda.
The agenda includes a Product Safety and Metrology Bill. Some form of legislation to address UK product regulation was expected in order to take account of market developments and new technologies, such as online selling and AI. We set out below a brief summary of the Bill.
Continue Reading The King’s Speech: Product Safety and Metrology BillWhat does the new UK government mean for life sciences?
In the UK General Election on 4 July, the Labour Party won 412 of the 650 seats, giving it a comfortable majority. Its leader, Sir Keir Starmer, became Prime Minister, meaning a change of government from Conversative to Labour for the first time in 14 years.
In its campaign, Labour focused on the need to deliver economic growth and innovation in critical industry sectors. It also placed considerable emphasis on addressing the problems facing the National Health Service (NHS), such as long waiting lists for treatment, old equipment and an increasingly ageing population.
The government’s economic priorities were further set out in the first major speech delivered by the new Chancellor of the Exchequer Rachel Reeves on 8 July, in which she said that growth “is now our national mission”. The Health Secretary Wes Streeting also noted his intention of making the Department of Health and Social Care a department for economic growth. While each of these are statements of intent and not binding on the new government, they provide valuable insight into what industry can expect over the next 5 years. We set out below some of the most relevant initiatives that could impact the industry.
Continue Reading What does the new UK government mean for life sciences?